Table S14 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors

Ismael A. Vergara; Nigel G. Maher; Alison J. Potter; Elizabeth C. Paver; Jordan W. Conway; Serigne Lo; Andrew J. Colebatch; Georgina V. Long; James S. Wilmott; Richard A. Scolyer

doi:10.1158/1078-0432.30029183

September 2, 2025Open Access

Table S14 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors

View Full Paper

Ask AI

Bookmark

Share

Key Points

It shows a high probability of melanoma for borderline conventional tumors, emphasizing the significance of genomic features.
Key evidence includes the inclusion of COSMIC identifiers for coding mutations that help determine malignancy.
Assessment of clinical, pathological, and genomic features highlights the role of ancillary tests in improving patient diagnostics.
This may enhance melanoma detection strategies, particularly for borderline conventional tumors, but requires further validation.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Clinical analysis shows high probability of melanoma in borderline tumors, suggesting improved diagnostics.

Abstract

Clinical, pathological and genomic features for Tier 2 borderline conventional tumors with high probability of melanoma. Additional ancillary test results are included when available from the patients’ report. Catalogue of Somatic Mutations in Cancer (COSMIC) identifiers for coding mutations are included.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Vergara et al. (2025) studied this question.

synapsesocial.com/papers/68c182609b7b07f3a060f5c6 https://doi.org/10.1158/1078-0432.30029183

View Full Paper

Ask AI

Bookmark

Share

Table S14 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Table S14 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading